SLC5A2 and urinary bladder cancer: SGLT‐2 inhibitors may increase the risk of genital tract infections secondary to their mechanism of action23, 24, 25; however, investigation into these infections (eg urinalysis) may prompt further diagnostic workup and eventual diagnosis of bladder cancers that were present before initiation of SGLT‐2 inhibitor therapy.